Swiss double Covid vaccine order from Pfizer/BioNTech
Switzerland has ordered enough to vaccinate the population more than two times over.
Keystone / Fazry Ismail
The Swiss government has signed a new deal with Pfizer/BioNTech for another three million vaccine doses, bringing the total number of doses ordered from five companies to nearly 36 million.
The additional doses will be delivered to Switzerland in April, according to the government. When announcing the “good news”, health minister Alain Berset tweeted that “one million (doses) will already be available in the cantons in April, May and June”.
This comes amid concerns about the slow pace of the vaccine rollout. To date, only 1.3 million doses have been delivered and around 3.8% of the population has been fully vaccinated. As a comparison, in Israel, which has about the same population as Switzerland, more than 40% of the population is fully vaccinated.
During a press conference yesterday, Nora Kronig, deputy director of the Federal Office of Public Health, said vaccinations were still progressing according to plan. “We are still confident that by the end of June we will be able to vaccinate anyone who wants to,” Kronig told reporters.
Spreading its purchases
Switzerland has so far bought more than 35 million doses for its population of 8.6 million. These doses are from five manufacturers: Moderna (13.5 million doses), Pfizer/BioNTech (now around 6 million), Oxford/AstraZeneca (around 5.3 million), Curevac (5 million) and Novavax (6 million).
In a statementExternal link, the government said “given that production and availability of vaccines are subject to such great uncertainty, the federal government continues to look into different vaccine technologies from different vaccine manufacturers”. However, it is focusing on mRNA vaccines because they are “proving to be highly effective and well tolerated”. Four out of the five vaccines ordered are mRNA-based.
So far, only the Pfizer and Moderna vaccines have been approved by the Swiss medical regulator Swissmedic. CureVac and Novavax have not yet filed for approval and Oxford/AstraZeneca’s vaccine is still being reviewed. Swissmedic has said that based on the available data, the safety, efficacy and quality of the vaccine could not be conclusively evaluated. It is still awaiting results of large-scale clinical trials from Oxford/AstraZeneca.
Popular Stories
More
Workplace Switzerland
Trump tariff shock: how Switzerland is positioning itself
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
This content was published on
Around 50 caravans belonging to members of a travelling community attempting to enter canton Valais in southern Switzerland without prior warning were blocked by police.
Swiss consumer spending rises in March despite tariff uncertainties
This content was published on
Global financial turmoil and uncertainties surrounding trade tariffs have not yet had an impact on consumer behaviour in Switzerland, where spending rose strongly in March.
Swiss road safety group warns of e-scooter dangers
This content was published on
Accidents involving electric scooters often result in injuries to the head, face or upper body, the Swiss Council for Accident Prevention BFU warns.
This content was published on
The number of eggs consumed in Switzerland last year smashed the annual record, according to the Federal Office for Agriculture (FOAG).
This content was published on
Switzerland emitted 40.8 million tonnes of CO2 equivalents in 2023, 1 million tonnes less than the previous year. Overall, emissions were 26% lower than in 1990.
Swiss soldiers take part in military exercise in Austria
This content was published on
The Swiss army has organised a military exercise in Austria, involving 1,000 militia soldiers. The aim is to strengthen the country's defence capability.
Switzerland records below-average number of avalanche deaths
This content was published on
Ten people died in avalanches in the Swiss Alps last winter, according to the WSL Institute for Snow and Avalanche Research (SLF). This is below the average for the past 20 years.
This content was published on
The Swiss population is expected to grow to 10.5 million by 2055, mainly due to immigration, according to the latest forecast by the Federal Statistical Office (FSO).
WMO climate report: warmest year and record rainfall in Europe in 2024
This content was published on
Europe faced a stark east-west climate divide last year: it was too wet in the west and too dry in the east, according to a new report.
Trump tariffs: 95% of Swiss SMEs don’t plan to move to US
This content was published on
According to a survey, 95% of small and medium-sized industrial companies (SMEs) in Switzerland are not planning to relocate to the United States in the near future.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
This content was published on
Switzerland will be affected by the temporary delay to the Pfizer-BioNTech Covid-19 vaccine in Europe, the Swiss health authorities have confirmed.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.